Ensign Peak Advisors
CPRX

Ensign Peak Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Ensign Peak Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,160
Closed -$177K – 1729
2026
Q1 		$177K Hold
7,160
– – ﹤0.01% 1363
2025
Q4 		$167K Sell
7,160
-13,850
-66% -$309K ﹤0.01% 1392
2025
Q3 		$414K Sell
21,010
-27,150
-56% -$558K ﹤0.01% 1470
2025
Q2 		$1.05M Hold
48,160
– – ﹤0.01% 1223
2025
Q1 		$1.17M Hold
48,160
– – ﹤0.01% 1167
2024
Q4 		$1.01M Hold
48,160
– – ﹤0.01% 1314
2024
Q3 		$957K Hold
48,160
– – ﹤0.01% 1345
2024
Q2 		$746K Hold
48,160
– – ﹤0.01% 1458
2024
Q1 		$768K Sell
48,160
-2,430
-5% -$36.6K ﹤0.01% 1484
2023
Q4 		$850K Hold
50,590
– – ﹤0.01% 1472
2023
Q3 		$591K Hold
50,590
– – ﹤0.01% 1540
2023
Q2 		$680K Hold
50,590
– – ﹤0.01% 1520
2023
Q1 		$839K Hold
50,590
– – ﹤0.01% 1391
2022
Q4 		$941K Buy
50,590
+25,350
+100% +$390K ﹤0.01% 1211
2022
Q3 		$324K Buy
25,240
+23,820
+1,677% +$282K ﹤0.01% 1672
2022
Q2 		$10K Buy
+1,420
New +$10.4K ﹤0.01% 2144

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ensign Peak Advisors's CPRX Position: Q2 2026 in Review

Ensign Peak Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 7,160 shares — an estimated $177K sold.

Ensign Peak Advisors first reported a position in CPRX in Q2 2022 and held it in 16 quarters. The position peaked at $1.17M in Q1 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Ensign Peak Advisors reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Ensign Peak Advisors sold 7,160 Catalyst Pharmaceutical shares in Q2 2026, an estimated $177K.
  • Ensign Peak Advisors first reported a position in Catalyst Pharmaceutical in Q2 2022 and held it in 16 quarters.
  • Ensign Peak Advisors's Catalyst Pharmaceutical position peaked at $1.17M in Q1 2025.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.